drugset / Trial / NCT05561699
Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study used an open single center study design to observe the efficacy and safety of Penpulimab combined with Chemoradiotherapy(CRT) in preoperative T2,3,4aN0-1-2M0 esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2022-09-28
- Primary completion
- 2024-09-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Dexamethasone | Small molecule | 10 mg | Intramuscular |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | Intravenous |